0000000000539026

AUTHOR

V. Rizzo

showing 5 related works from this author

Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B ‘e’ antigen-negative chronic hepatitis B genot…

2019

Nucleos(t)ide analogues (NAs) and peginterferon have complementary effects in chronic hepatitis B, but it is unclear whether combination therapy improves responses in genotype D-infected patients. We conducted an open-label study of peginterferon alfa-2a 180 μg/week added to ongoing NA therapy in hepatitis B e antigen (HBeAg)-negative, genotype D-infected patients with HBV DNA <20 IU/mL. The primary endpoint was proportion of patients with ≥50% decline in serum HBsAg by the end of the 48-week add-on phase. Seventy patients received treatment, 11 were withdrawn at week 24 for no decrease in HBsAg, and 14 withdrew for other reasons. Response rate (per-protocol population) was 67.4% (29/43) at…

MaleHBsAgGastroenterologyPolyethylene Glycolschronic hepatitis B; HBeAg-negative; nucleos(t)ide analogues; peginterferon; treatment; Hepatology; Infectious Diseases; Virology0302 clinical medicineInterferonGenotypeHBVHepatitis B e Antigenspeginterferonchronic hepatitis b; hbeag-negative; nucleos(t)ide analogues; peginterferon; treatment; adult; antiviral agents; drug administration schedule; drug therapy combination; female; genotype; hepatitis b e antigens; hepatitis b virus; hepatitis b chronic; humans; interferon-alpha; male; middle aged; nucleosides; polyethylene glycols; recombinant proteins; treatment outcomeeducation.field_of_studytreatmentnucleos(t)ide analoguesvirus diseasesNucleosidesMiddle AgedRecombinant ProteinsTreatment OutcomeInfectious Diseasesnucleos(t)ide analogueHBeAg030220 oncology & carcinogenesisDrug Therapy CombinationFemale030211 gastroenterology & hepatologyPeginterferon alfa-2amedicine.drugAdultHepatitis B virusmedicine.medical_specialtyGenotypeCombination therapyPopulationHBeAg-negativeInfectious DiseaseHBeAg-negative; chronic hepatitis B; nucleos(t)ide analogues; peginterferon; treatmentchronic hepatitis B; HBeAg-negative; nucleos(t)ide analogues; peginterferon; treatmentAntiviral AgentsDrug Administration Schedule03 medical and health sciencesHepatitis B ChronicInternal medicineVirologymedicineHumanschronic hepatitis BeducationHepatologybusiness.industryInterferon-alphaConfidence intervalbusiness
researchProduct

Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort

2020

Abstract Objectives To describe: (i) factors associated with rapid and delayed ART initiation; (ii) rates of 12 week virological response; and (iii) virologically controlled retention in care by 1 year from ART initiation according to timing of start in a real-life setting. Methods All individuals in the Icona cohort diagnosed with HIV in 2016–17 who initiated ART were grouped according to the time between HIV diagnosis and ART initiation: Group 1, ≤7 days; Group 2, 8–14 days; Group 3, 15–30 days; Group 4, 31–120 days; and Group 5, &amp;gt;120 days. Multivariable logistic regression models were used to identify factors associated with: (i) the probability of rapid (Group 1) and very delayed…

0301 basic medicinediagnosishivcommunicable diseasesHIV InfectionsLogistic regressionVirological responseCohort Studies0302 clinical medicineRetention in CareMedicinePharmacology (medical)HIV Infection030212 general & internal medicineProspective cohort studycd4 count determination proceduredrugsuppressionViral LoadCD4 Lymphocyte Count; Cohort Studies; Humans; Italy; Viral Load; Anti-HIV Agents; HIV Infections; Retention in CarevirologyInfectious DiseasesItalyblood hiv rnaCohorthiv cd4 count determination procedure communicable diseases incomeitaly diagnosis virology blood hiv rna retention in careincomeitalyViral loadHIV ARTCohort studyHumanMicrobiology (medical)medicine.medical_specialtyAnti-HIV Agentsantiretroviral therapySettore MED/17 - MALATTIE INFETTIVENO03 medical and health sciencesHIV viral loadInternal medicineHumansHIV CD4 ARTPharmacologybusiness.industrydouble blindAnti-HIV AgentHIV viral load antiretroviral therapy double blind initiation suppression infectionRetention in care030112 virologyinfectioninitiationCD4 Lymphocyte CountObservational studyCohort Studiebusiness
researchProduct

The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation …

2021

HCV infection has been hypothesized as a contributor of poor CD4+ recovery in patients living with HIV (PLWHIV). Aim of this study was to evaluate CD4+, CD8+ cells and CD4/CD8 ratio trends before and after HCV treatment with direct acting agents (DAA) in PLWHIV. HIV/HCV patients enrolled in ICONA and HepaICONA cohorts with HIV-RNA≤50 copies/ml who achieved a sustained viral response after DAA treatment were studied. A linear regression model was used to investigate CD4+, CD8+ and CD4/CD8 changes 12 months before and after DAA treatment. A total of 939 HIV/HCV patients were included, 225 (24.0%) female, median age: 53 years (IQR 50–56). At DAA initiation, CD4+ T cell count was &lt;350 cells/…

CD4-Positive T-LymphocytesHIV InfectionsHepacivirusCD8-Positive T-LymphocytesGastroenterologySettore MED/07chemistry.chemical_compound0302 clinical medicineCd8 t lymphocyteHIV Infection030212 general & internal medicineCoinfectionCD4; CD8; DAA; HCV/HIV; immune activationHcv clearancevirus diseasesMiddle AgedHepatitis CInfectious Diseasesmedicine.anatomical_structureCD4-Positive T-LymphocyteCohort030211 gastroenterology & hepatologyFemaleCD4 CD8 DAA HCV/HIV immune activationHumanImmune activationmedicine.medical_specialtyHCV/HIVT cellAntiviral Agentsimmune activationNO03 medical and health sciencesVirologyInternal medicinemedicineHumansIn patientimmune activation.DAAAntiviral AgentHepaciviruHepatologybusiness.industryRibavirinCD8-Positive T-LymphocyteCD8CD4CD4 Lymphocyte CountchemistryCD4; CD8; DAA; HCV/HIV; immune activation; Antiviral Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Hepacivirus; Humans; Middle Aged; Coinfection; HIV Infections; Hepatitis CbusinessCD8
researchProduct

Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?

2020

Abstract Background High uptake of antiretroviral treatment (ART) is essential to reduce human immunodeficiency virus (HIV) transmission and related mortality; however, gaps in care exist. We aimed to construct the continuum of HIV care (CoC) in 2016 in 11 European Union (EU) countries, overall and by key population and sex. To estimate progress toward the Joint United Nations Programme on HIV/AIDS (UNAIDS) 90-90-90 target, we compared 2016 to 2013 estimates for the same countries, representing 73% of the population in the region. Methods A CoC with the following 4 stages was constructed: number of people living with HIV (PLHIV); proportion of PLHIV diagnosed; proportion of those diagnosed …

Male0301 basic medicinePsychological interventionHuman immunodeficiency virus (HIV)MedizinContinuum of care; Europe; HIV infection; Key population; Sex; Anti-Retroviral Agents; Continuity of Patient Care; European Union; HIV; Humans; Male; HIV InfectionsHIV InfectionsContinuum of care; Europe; HIV infection; Key population; Sexmedicine.disease_causekey population0302 clinical medicineContinuum of careHIV Infection030212 general & internal medicineMen having sex with menContinuum of caremedia_commoneducation.field_of_study[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyTransmission (medicine)Continuity of Patient CareEuropeInfectious DiseasesAcademicSubjects/MED00290Anti-Retroviral AgentsHIV infection continuum of care sex key population EuropeSexMicrobiology (medical)PopulationSocio-culturale03 medical and health sciencesAcquired immunodeficiency syndrome (AIDS)SDG 3 - Good Health and Well-beingmedicinemedia_common.cataloged_instanceHumansEuropean UnionEuropean unioneducationPandemicsHIV infection ; continuum of care ; sex ; key population ; Europebusiness.industrySARS-CoV-2COVID-19HIVmedicine.diseaseHIV infectioncontinuum of care030112 virologyMajor Articles and CommentariesKey populationAnti-Retroviral Agentbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyDemography
researchProduct

Early outcomes and complications following cardiac surgery in patients testing positive for coronavirus disease 2019: An international cohort study

2021

The outbreak of severe acute respiratory syndromecoronavirus-2, the cause of coronavirus disease 2019 (COVID-19) in December 2019 represented a global emergency accounting for more than 2.5 million deaths worldwide.1 It has had an unprecedented influence on cardiac surgery internationally, resulting in cautious delivery of surgery and restructuring of services.2 Understanding the influence of COVID-19 on patients after cardiac surgery is based on assumptions from other surgical specialties and single-center studies. The COVIDSurg Collaborative conducted a multicenter cohort study, including 1128 patients, across 235 hospitals, from 24 countries demonstrating perioperative COVID-19 infection…

Pulmonary and Respiratory MedicineMale2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)complication.ArticleNOCohort Studiesoutcomes; complications; following cardiac surgery; coronavirus disease 2019Postoperative ComplicationsCardiovascular Diseases; Cohort Studies; Female; Humans; Male; Middle Aged; SARS-CoV-2; COVID-19; Cardiac Surgical Procedures; Postoperative ComplicationsInternal medicineCardiovascular DiseasemedicineCardiac Surgical ProcedureHumansIn patientCardiac Surgical ProceduresLS7_4business.industrySARS-CoV-2COVID-19Middle AgedCardiac surgeryCardiovascular DiseasesoutcomeSurgeryFemaleCohort StudieCardiology and Cardiovascular Medicinebusinesscardiac surgery[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyCohort studyHuman
researchProduct